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ABSTRACT
The efficacy of voriconazole in combination with
amphotericin B or micafungin was studied in a
transiently neutropenic guinea-pig model of inva-
sive pulmonary aspergillosis. Guinea-pigs treated
with the antifungal drugs, alone or in two-drug
combinations, had an improved survival rate and
reduced fungal burden in the lungs compared
to untreated control animals. The efficacy of
monotherapy and combination therapy was sim-
ilar; activity was neither enhanced nor reduced
with the two-drug combinations. Further studies
of efficacy, dosing and optimal regimens for
antifungal combinations are warranted.
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Invasive aspergillosis is an escalating clinical
problem with high mortality [1–3]. The standard
drugs for treatment include amphotericin B (or its
lipid form) and itraconazole, but neither agent is
totally effective [3]. Voriconazole has been
approved recently in the USA for the treatment
of invasive aspergillosis, and has a response rate
of c. 50% [4]. Caspofungin acetate, a new anti-
fungal agent in the echinocandin family, has been
shown to be effective in c. 40% of patients with
refractory aspergillosis [5]. Given this sub-optimal
outcome with antifungal monotherapy, an attract-
ive option is a combination of drugs from differ-
ent classes with distinct target sites.
In-vitro data suggest that the activity of anti-
fungal combinations of an azole plus polyene,
azole plus echinocandin, or polyene plus echino-
candin, against aspergillosis may range from an
additive effect to synergism [6–8]. Data from
animal studies are sparse [9], but the superior
efficacy of voriconazole over amphotericin B has
been demonstrated previously in a transiently
neutropenic guinea-pig model of invasive pul-
monary aspergillosis [10]. With the same model,
the present study evaluated the efficacy of a
reduced dose of voriconazole in combination with
amphotericin B or micafungin (an echinocandin).
The Aspergillus fumigatus strain used in this
study, W73355 (ATCC 208996), was a clinical
isolate obtained from the Detroit Medical Center.
This organism was susceptible to amphotericin B,
voriconazole (MICs of 0.5 mg ⁄L and 0.25 mg ⁄L,
respectively) and micafungin (minimal effective
concentration 0.03 mg ⁄L). Working cultures were
maintained on Sabouraud dextrose agar slants at
4C. The drugs used were amphotericin B deo-
xycholate (Fungizone; Bristol Meyers Squibb,
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Princeton, NJ, USA), voriconazole (Pfizer Phar-
maceuticals, New York, NY, USA) and micafun-
gin (Fujisawa Pharmaceutical Company, Osaka,
Japan). Female Hartley guinea-pigs weighing
350 ± 50 g were rendered neutropenic by three
successive intraperitoneal injections of cyclo-
phosphamide (100 mg ⁄ kg) on days ) 3, ) 1 and
+ 1, where day 0 represents the day of infection.
Leukocyte counts were monitored throughout the
experiment. Animals were anaesthetised by
intraperitoneal injections of ketamine 40 mg ⁄ kg
plus xylazine 5 mg ⁄kg, as described elsewhere
[11]. The tracheal wall was exposed by blunt
dissection, and 0.2 mL of a conidial suspension
containing 5 · 107 conidia ⁄mL was injected into
the trachea via a 25-gauge needle. The infected
animals were divided into five treatment groups,
each containing 14–20 animals. Each group
received one of the following therapies: intraperi-
toneal amphotericin B 1 mg ⁄ kg ⁄day; intraperito-
neal micafungin 2 mg ⁄ kg ⁄day; oral voriconazole
5 mg ⁄ kg twice-daily; oral voriconazole 5 mg ⁄ kg
twice-daily plus intraperitoneal amphotericin B
1 mg ⁄ kg ⁄day or micafungin 2 mg ⁄ kg ⁄day. Con-
trol animals received either phosphate-buffered
saline or polyethylene glycol 200 as a placebo.
Treatment was continued for 7 days.
The efficacy of the antifungal treatment was
defined in terms of increased survival rate,
decreased fungal burden, and complete sterility
of the lungs in treated animals. Fig. 1 shows the
survival data and fungal burden in the lungs of
infected animals (deceased or killed humanely)
treated with voriconazole alone, amphotericin B
alone, or voriconazole plus amphotericin B, and
untreated controls. At the end of 1 week, > 70% of
the controls had died. Animals treated with
monotherapy (voriconazole or amphotericin B)
or voriconazole plus amphotericin B had an
improved survival rate compared with untreated
controls (p < 0.05). There was no significant dif-
ference between the groups receiving voriconazole
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Fig. 1. Efficacy of voriconazole (VCZ), amphotericin B
(AMB) and voriconazole plus amphotericin B in the
treatment of pulmonary aspergillosis in guinea-pigs. The
data are presented as (a) percentage survival and (b)
fungal burden (CFU ⁄ lungs) of infected animals
(14 ⁄ group).
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Fig. 2. Efficacy of voriconazole (VCZ), micafungin (MFG)
and voriconazole plus micafungin in the treatment of
pulmonary aspergillosis in guinea-pigs. The data are
presented as (a) percentage survival and (b) fungal burden
(CFU ⁄ lungs) of infected animals (17–20 ⁄ group).
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alone or voriconazole plus amphotericin B. Drug-
treated animals hadmarkedly reduced fungal bur-
dens compared with untreated controls (p < 0.05),
but there was no significant difference between the
combination and monotherapy regimens.
Fig. 2 shows similar data regarding the effica-
cies of voriconazole and voriconazole plus mica-
fungin. Both the mortality and the fungal burden
in drug-treated animals were reduced substan-
tially compared with the controls (p < 0.05).
However, no significant positive or negative
differences in the parameters were seen between
the three drug-treated groups. The results were
unchanged when the fungal burdens of deceased
animals and those killed humanely were analysed
separately.
Previous in-vitro and in-vivo observations have
suggested that there is a negative effect when an
azole is combined with amphotericin B for treat-
ment of aspergillosis [12,13], but more recent
in-vitro data have shown no negative impact with
such combinations [6–8]. Indeed, synergy was
demonstrated when an echinocandin was com-
bined with amphotericin B. In the present study,
no negative interaction was noted with the com-
binations of voriconazole plus amphotericin B or
micafungin. Similar results were obtained by
Kirkpatrick et al. [9] in an evaluation of voricon-
azole plus caspofungin in a guinea-pig model of
disseminated aspergillosis. Thus, current data
suggest an absence of harm or a negative inter-
action when an azole is combined with a polyene
or an echinocandin for the treatment of invasive
aspergillosis. If the dose of voriconazole had been
reduced further, a difference in efficacy between
combination therapy and monotherapy may have
been demonstrated. However, Kirkpatrick et al.
[9] did not observe a synergic response with a
combination of a reduced dose of voriconazole
(5 mg ⁄ kg ⁄day) and caspofungin.
Human data on the efficacy of antifungal
combinations against invasive aspergillosis are
limited [14–16]. Information from the present
study adds to the increasing body of data sug-
gesting the absence of a negative effect with a
combination of an azole plus polyene, or azole
plus echinocandin, for the treatment of aspergil-
losis. Another triazole, ravuconazole, has been
reported to have an enhanced interaction when
combined with micafungin in a rabbit model of
invasive aspergillosis [17]. Additional studies to
determine optimal combination regimens for
improved efficacy with different agents in the
management of invasive aspergillosis are warran-
ted.
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ABSTRACT
Until recently, brain aspergillosis was almost
always fatal, with a response rate to amphotericin
B of < 10%. This study describes a retrospective
analysis of eight consecutive cases of brain
aspergillosis. All patients were immunosup-
pressed and five required mechanical ventilation.
Antifungal treatment included amphotericin B
(n = 7), itraconazole (n = 3), voriconazole (n = 2)
and flucytosine (n = 1). Three (38%) patients
survived following prolonged azole therapy after
initial amphotericin B treatment, combined with a
reduction in their immunosuppressive treatment.
The prognosis of brain aspergillosis might be
improved if immunosuppression could be
reduced and prolonged oral azole therapy used.
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Invasive aspergillosis is a major cause of morbid-
ity and mortality in immunosuppressed patients
[1–3]. In a cohort study in 1994–1995, complete or
partial responses were seen in 132 (40%) of 330
patients with pulmonary invasive aspergillosis,
and in 23 (16%) of 148 patients with disseminated
aspergillosis [1]. Central nervous system involve-
ment corresponded with the poorest response
rate, with complete or partial response reported in
three (9%) of 34 patients. A review in 1996
reported a crude mortality rate of 99% (140 ⁄ 141
patients) in cases of brain aspergillosis [4]. How-
ever, the development of new azoles active
against aspergillosis might improve this situation.
To investigate this possibility, eight consecutive
patients with brain aspergillosis admitted to the
Infectious Diseases intensive care unit (ICU) at
Bichat-Claude Bernard Hospital (a 1200-bed uni-
versity-affiliated teaching hospital that serves as a
referral centre in the metropolitan Paris area)
were analysed retrospectively.
Brain aspergillosis was defined by the three
following criteria: (1) at least one predisposing
condition for invasive aspergillosis (bone marrow
transplant, haematological malignancy, chronic
neutropenia, immunosuppressive treatment); (2)
at least one localised lesion visible on computer-
ised tomography brain scan and ⁄ or magnetic
resonance imaging in the absence of an alternative
diagnosis; and (3) isolation ofAspergillus spp. from
culture of intracerebral material, bronchoalveolar
lavage or sinus samples, or hyphae consistent with
the presence of Aspergillus spp. in a biopsy of brain
tissue. All patients had definite or probable inva-
sive aspergillosis according to the consensus
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